Contingency Management for Cannabis Use Disorder in Adolescents
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how cannabis affects certain brain systems in adolescents and aims to identify biomarkers that can predict relapse after quitting. The treatment under study, Contingency Management, rewards participants for abstaining from cannabis. The trial seeks participants aged 14 to 25 who have used cannabis at least twice a week in the past month. As an unphased study, it offers a unique opportunity to contribute to groundbreaking research that could benefit future treatments.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, you cannot participate if you have used opioid medications in the past 90 days.
What prior data suggests that Contingency Management is safe for adolescents?
Research has shown that Contingency Management (CM) is a safe and effective method for helping individuals quit cannabis. CM provides rewards for positive actions, such as avoiding cannabis. Studies have found that it reduces cannabis use and helps maintain abstinence, even in those with mental health issues like depression. This approach has been successful with young adults and teens struggling with cannabis use. No major safety problems have been reported, and most participants find CM manageable. Overall, it is considered a safe way to help teens stop using cannabis.12345
Why are researchers excited about this trial?
Unlike the standard treatments for Cannabis Use Disorder, which often include behavioral therapies and medications, Contingency Management (CM) stands out by using a reward-based approach. This method incentivizes abstinence by providing tangible rewards for staying cannabis-free, which can be more motivating for adolescents. Researchers are excited about CM because it directly targets behavior through positive reinforcement, potentially leading to higher engagement and success rates compared to traditional methods that might not appeal as strongly to younger individuals.
What evidence suggests that Contingency Management is effective for Cannabis Use Disorder?
Research has shown that Contingency Management (CM), the treatment under study in this trial, can help people reduce or quit cannabis use. CM encourages sobriety through rewards. It has effectively helped individuals with conditions such as depression or psychotic disorders reduce cannabis use. Financial incentives play a significant role in motivating habit change. However, results can vary; some studies suggest CM might not work for everyone. Overall, CM shows promise in helping people quit or reduce cannabis use by providing tangible rewards for their progress.12367
Are You a Good Fit for This Trial?
This trial is for adolescents aged 14 to 25 who use cannabis at least twice a week over the past month. It's not open to those using other illicit drugs or opioids recently, with current psychosis, risk of suicide, intellectual deficiencies that affect consent understanding, without internet access for Zoom, or if they're intoxicated during evaluation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Measurement
Measure endocannabinoid and endogenous opioid levels in adolescents who use cannabis regularly and those who do not
Abstinence Monitoring
Characterize circulating eCB and endorphin levels during abstinence and collect data on cannabis craving
Follow-up
Participants are monitored for changes in eCB and endorphin levels after natural resumption of cannabis use
What Are the Treatments Tested in This Trial?
Interventions
- Contingency Management
Contingency Management is already approved in United States, European Union for the following indications:
- Substance Use Disorders
- Stimulant Use Disorder
- Methamphetamine Use Disorder
- Substance Use Disorders
- Addiction Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
Colorado Clinical & Translational Sciences Institute
Collaborator